Market closed
Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15,106
Website
Regeneron Metrics
BasicAdvanced
$68B
16.62
$38.34
0.27
$0.88
0.55%
Price and volume
Market cap
$68B
Beta
0.27
52-week high
$1,206.81
52-week low
$629.02
Average daily volume
918K
Dividend rate
$0.88
Financial strength
Current ratio
5.567
Quick ratio
4.935
Long term debt to equity
9.908
Total debt to equity
10.012
Interest coverage (TTM)
76.58%
Management effectiveness
Return on assets (TTM)
7.31%
Return on equity (TTM)
15.95%
Valuation
Price to earnings (TTM)
16.624
Price to revenue (TTM)
4.842
Price to book
2.34
Price to tangible book (TTM)
2.43
Price to free cash flow (TTM)
19.433
Dividend yield (TTM)
0.14%
Forward dividend yield
0.55%
Growth
Revenue change (TTM)
8.27%
Earnings per share change (TTM)
10.27%
3-year revenue growth (CAGR)
-4.04%
3-year earnings per share growth (CAGR)
-18.94%
What the Analysts think about Regeneron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Regeneron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Regeneron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Regeneron News
AllArticlesVideos
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewsWire·4 days ago
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
GlobeNewsWire·4 days ago
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $68B as of March 31, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 16.62 as of March 31, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of March 31, 2025, the dividend rate is $0.88 and the yield is 0.55%. Regeneron has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment date is unconfirmed.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.